oral semaglutide approval US FDA accepts Novo Nordisk's application for Wegovy for weight loss Best Semaglutide Options for 2026:

Enhanced Affinity: It dramatically enhances its affinity for IGF-1 receptors in damaged muscle cells

The diagnosis of adrenal insufficiency is established by the 24-hour corticotropin-stimulation test

According to the Summary of Product Characteristics (SmPCs), GLP-1 medications commonly cause nausea (reported in approximately 20-40% of patients with semaglutide and 12-21% with dulaglutide), vomiting, and diarrhoea, particularly during initial treatment and dose escalation

The incretin hormones GLP-1 and GIP (targeted by semaglutide and tirzepatide respectively) regulate postprandial insulin secretion and suppress appetite via central mechanisms forming the basis of GLP-1 receptor agonist pharmacotherapy